Global Cystic Fibrosis Market 2015-2019

嚢胞性線維症(CF症)治療薬の世界市場

◆タイトル:Global Cystic Fibrosis Market 2015-2019
◆商品コード:IRTNTR4842
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年12月17日
◆ページ数:126
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Five UserUSD3,300 ⇒換算¥363,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、嚢胞性線維症(CF症)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、嚢胞性線維症(CF症)治療薬の世界市場規模及び予測、投与経路(ROA)別分析、市場シェア、地域別分析、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Cystic Fibrosis
Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country.
Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and secretion of abnormal viscous mucus are the major symptoms of cystic fibrosis.

TechNavio’s analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.50 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Cystic Fibrosis market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes:
• Small Molecules
• Biologics
Further, the market is segmented on based on route of administration and dosage form. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cystic Fibrosis market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Cystic Fibrosis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Actavis
• F. Hoffmann-La Roche
• Gilead Sciences
• Novartis
• Vertex Pharmaceuticals

[Other Prominent Vendors]
• Abbott
• Anthera Pharmaceuticals
• Arcturus Therapeutics
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Insmed
• Pharmaxis
• PharmaSwiss
• Genzyme
• Johnson & Johnson
• Merck Sharp & Dohme
• Neovii Biotech
• Novo Nordisk
• Proteostasis Therapeutics
• PTC Therapeutics
• United Medical
• Venus Remedies

[Market Driver]
• Unmet Needs in the Market
• For a full, detailed list, view our report

[Market Challenge]
• Expensive Treatment
• For a full, detailed list, view our report

[Market Trend]
• Increase in Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Zenpep/ Ultresa/ Ultrase/ Ultrase MT
04.1.2 Colomycin/ Colobreathe
04.1.3 Pulmozyme
04.1.4 Cayston
04.1.5 TOBI/ TOBI Podhaler
04.1.6 Kalydeco

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.2 Pathophysiology
07.3 Epidemiology
07.3.1 Global
07.3.2 North America
07.3.3 Europe
07.3.4 Africas
07.3.5 Latin America
07.3.6 Middle East
07.3.7 Asia and Oceania
07.4 Diagnosis
07.4.1 Newborn Screening
07.4.2 Carrier Testing
07.4.3 Antenatal Testing
07.4.4 Other Tests
07.5 Manifestations of Cystic Fibrosis
07.6 Economic Burden

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Molecule Type
09.1 Biologics
09.1.1 Enzymes
09.2 Small Molecules
09.2.1 CFTR Modulator
09.2.2 Antibiotics

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
10.3 Topical

11.Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid

12.Geographical Segmentation
12.1 Cystic Fibrosis Market in the Americas
12.1.1 Cystic Fibrosis Market in the US
12.1.2 Cystic Fibrosis Market in the Latin America
12.1.3 Cystic Fibrosis Market in the Canada
12.2 Cystic Fibrosis Market in the EMEA Region
12.2.1 Market Size and Forecast
12.3 Cystic Fibrosis Market in the APAC Region
12.3.1 Market Size and Forecast

13.Key Leading Countries
13.1 US
13.2 UK
13.3 France
13.4 Canada
13.5 Italy

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 F. Hoffmann-La Roche
21.2.2 Novartis
21.2.3 Vertex Pharmaceuticals
21.2.4 Actavis
21.2.5 Gilead Sciences
21.3 Other and Future Prominent Vendors

22.Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
21.1.4 Revenue by Business Segmentation
22.1.5 Revenue Comparison 2013 and 2014
22.1.6 Sales by Geography
22.1.7 Business Strategy
22.1.8 Key Developments
22.1.9 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Description
22.2.3 Business Segmentation
22.2.4 Revenue by Business Segmentation
22.2.5 Revenue Comparison 2013 and 2014
22.2.6 Sales by Geography
22.2.7 Business Strategy
22.2.8 Key Developments
22.1.9 SWOT Analysis
22.3 Gilead Sciences
22.3.1 Key Facts
22.3.2 Business Description
22.3.3 Business Segmentation
22.3.4 Revenue by Business Segmentation
22.3.5 Revenue Comparison 2013 and 2014
22.3.6 Sales by Geography
22.3.7 Business Strategy
22.3.8 Key Developments
22.3.9 SWOT Analysis
22.4 Novartis
22.4.1 Key Facts
22.4.2 Business Description
21.4.3 Business Segmentation
22.4.4 Revenue by Business Segmentation
22.4.5 Revenue Comparison 2013 and 2014
22.4.6 Sales by Geography
22.4.7 Business Strategy
22.4.8 Key Developments
22.4.9 SWOT Analysis
22.5 Vertex Pharmaceuticals
22.5.1 Key Facts
22.5.2 Business Description
22.5.3 Business Segmentation
22.5.4 Revenue by Business Segmentation
22.5.5 Revenue Comparison 2013 and 2014
22.5.6 Sales by Geography
22.5.7 Business Strategy
22.5.8 Key Developments
22.5.9 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot Of Cystic Fibrosis Disease
Exhibit 3: Defects Caused by CFTR Mutation
Exhibit 4: Epidemiology of Cystic Fibrosis in the World 2012
Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014
Exhibit 6: Prevalence Number of Cystic Fibrosis by Country 2014
Exhibit 7: Snapshot of US Prevalence of Cystic Fibrosis 2014
Exhibit 8: Forecast of Cystic Fibrosis Prevalence in US 2014-2019
Exhibit 9: Epidemiology Based on the Education Level in US, 2011
Exhibit 10: Epidemiology based on the Marital Status in US, 2011
Exhibit 11: Epidemiology based on the Employment Status in US, 2011
Exhibit 12: Forecast of Cystic Fibrosis Prevalence in Canada 2014-2019
Exhibit 13: Forecast of Cystic Fibrosis Prevalence in the UK 2014-2019
Exhibit 14: Age Distribution at Death for Cystic Fibrosis Patients in UK, 2013
Exhibit 15: Age Distribution by Gender for Cystic Fibrosis Patients in the UK, 2013
Exhibit 16: Age Distribution by Sex for Cystic Fibrosis Patients in the UK, 2013
Exhibit 17: Diagnosis of Cystic Fibrosis
Exhibit 18: The Manifestations of Cystic Fibrosis
Exhibit 19: Snapshot of the Economic Burden of Cystic Fibrosis
Exhibit 20: Snapshot of Global Cystic Fibrosis Market 2014
Exhibit 21: Global Cystic Fibrosis Market 2014-2019 (US$ million)
Exhibit 22: Global Cystic Fibrosis Market Segmentation By Class of Drugs
Exhibit 23: Global Cystic Fibrosis Drugs Market Segmentation by Molecule Type 2014
Exhibit 24: Global Cystic Fibrosis Market Segmentation By Route Of Administration
Exhibit 25: Global Cystic Fibrosis Drugs Market Segmentation by Route of Administration 2014
Exhibit 26: Global Cystic Fibrosis Market Segmentation by Dosage Form
Exhibit 27: Global Cystic Fibrosis Drugs Market Segmentation by Dosage Form 2014
Exhibit 28: Global Cystic Fibrosis Market by Geographical Segmentation 2014 and 2019
Exhibit 29: Global Cystic Fibrosis Market Revenue by Geographical Segmentation 2014-2019 (US$ million)
Exhibit 30: Global Cystic Fibrosis Market Growth Rate by Region 2014-2019
Exhibit 31: Revenue (US$ million) and CAGR of Global Cystic Fibrosis Market by Geographical Segments 2014 and 2019
Exhibit 32: Global Cystic Fibrosis Market by Country/Region 2014
Exhibit 33: Global Cystic Fibrosis Market by Country/Region 2014 (US$ million)
Exhibit 34: Cystic Fibrosis Market in the Americas 2014-2019 (US$ million)
Exhibit 35: Cystic Fibrosis Market Revenue in the Americas 2014-2019
Exhibit 36: Cystic Fibrosis Market Growth Rate in the Americas 2014-2019
Exhibit 37: Cystic Fibrosis Market in the Americas by Region 2014 and 2019
Exhibit 38: Revenue (US$ million) and CAGR of Cystic Fibrosis Market in the Americas by Regions 2014 and 2019
Exhibit 39: Cystic Fibrosis Market in the US 2014-2019 (US$ million)
Exhibit 40: Cystic Fibrosis Market in the Latin America 2014-2019 (US$ million)
Exhibit 41: Cystic Fibrosis Market in Canada 2014-2019 (US$ million)
Exhibit 42: Cystic Fibrosis Market in EMEA 2014-2019 (US$ million)
Exhibit 43: Cystic Fibrosis Market in EMEA by Country/Region 2014
Exhibit 44: Cystic Fibrosis Market in APAC 2014-2019 (US$ million)
Exhibit 45: Buying Criteria of Global Cystic Fibrosis Market
Exhibit 46: Global Cystic Fibrosis Market Share Analysis 2014
Exhibit 47: Global Sales Comparison of Pulmozyme 2013 vs 2012 (US$ Million)
Exhibit 48: Quarterly Sales Comparison of Pulmozyme in the US 1994-2008 (US$ Million)
Exhibit 49: Quarterly Sales Comparison of Pulmozyme Sales to Collaborators 1997-2008 (US$ Million)
Exhibit 50: Quarterly Sales Comparison of Pulmozyme Total Sales 1994-2008 (US$ Million)
Exhibit 51: Total Global Sales Comparison of Pulmozyme 1994-2008 (US$ Million)
Exhibit 52: TOBI Podhaler
Exhibit 53: YoY Sales Comparison of TOBI and TOBI Podhaler 2006-2013 (US$ Million)
Exhibit 54: YoY Sales Comparison of Kalydeco 2012-2013 (US$ Million)
Exhibit 55: Actavis: Business Segmentation 2014
Exhibit 56: Actavis: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 57: Actavis : Sales by Geography (in US$ million)
Exhibit 67: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2013 and 2014
Exhibit 68: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Pharmaceuticals Division)
Exhibit 69: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Diagnostics Division)
Exhibit 63: Gilead Sciences: Business Segmentation by Revenue 2014
Exhibit 64: Gilead Sciences: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 65: Gilead Sciences: Sales by Geography 2014
Exhibit 18: Novartis AG: Business Segmentation
Exhibit 19: Novartis AG: Revenue by Business Segmentation 2014
Exhibit 20: Novartis AG: Revenue by Business Segmentation 2013 and 2014 (US$ million)
Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2014
Exhibit 63: Vertex Pharmaceuticals: Business Segmentation by Revenue 2014
Exhibit 64: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 65: Vertex Pharmaceuticals: Sales by Geography 2014



【掲載企業】

Actavis , F. Hoffmann-La Roche , Gilead Sciences , Novartis , Vertex Pharmaceuticals , Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics , Boehringer Ingelheim , Chiesi Farmaceutici, Insmed, Pharmaxis , PharmaSwiss , Genzyme, Johnson & Johnson , Merck Sharp & Dohme,Neovii Biotech, Novo Nordisk, Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies

【資料のキーワード】

嚢胞性線維症(CF症)、治療薬、医薬品、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[嚢胞性線維症(CF症)治療薬の世界市場] (Global Cystic Fibrosis Market 2015-2019 / IRTNTR4842)販売に関する免責事項
[嚢胞性線維症(CF症)治療薬の世界市場] (Global Cystic Fibrosis Market 2015-2019 / IRTNTR4842)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆